Clinical Trials Sponsored by Humana Inc.

Total 38847 results

Humana Inc.
Boehringer Ingelheim; Humana Healthcare Research, Inc.

Active, not recruiting

Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
University of Miami
Humana Inc.

Completed

Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations

Coronary Artery Disease

United States
University of Miami
Humana Inc.

Completed

Improving Adherence to Statins Among Minority Populations

Dyslipidemia

United States
National Bureau of Economic Research, Inc.
Humana Inc.

Completed

Increasing Medication Adherence Through Physician Incentives and Messaging

Medication Adherence

United States
EicOsis Human Health Inc.

Completed

Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

Healthy Adults

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Hepatitis C, Chronic

Canada, Australia, Israel, Germany, Czech Republic, France, Poland, Romania
Human Genome Sciences Inc.

Completed

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada, Australia, India
Human Genome Sciences Inc.

Terminated

A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01

Rheumatoid Arthritis

United States, Poland
Human Genome Sciences Inc.

Completed

Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Human Genome Sciences Inc.

Completed

Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3

Chronic Hepatitis C

Canada
Human Genome Sciences Inc.

Withdrawn

Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis

Ulcerative Colitis
Waldkrankenhaus Protestant Hospital, Spandau
Humana Inc.

Completed

Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality

Overweight

Germany
EicOsis Human Health Inc.

Recruiting

Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy Subjects

Healthy Subjects

New Zealand
Human Genome Sciences Inc.

Completed

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

United States, Germany, Hungary, Romania
Human Genome Sciences Inc.

Completed

Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)

Lupus Erythematosus, Systemic

United States, Canada
Human Genome Sciences Inc.

Completed

Safety and Efficacy of an Antibody to CCR5 in Individuals With HIV Who Are Not Currently on Antiretroviral Therapy

HIV Infections

United States
Human Genome Sciences Inc.

Completed

Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States
EicOsis Human Health Inc.

Unknown

Cytokine and Eicosanoid Mediators in Coronavirus Disease 2019 (COVID-19)

COVID-19

United States
Human Genome Sciences Inc.

Completed

A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
Human Genome Sciences Inc.

Completed

A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

United States
Human Genome Sciences Inc.

Completed

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Hepatitis C

United States
Human Genome Sciences Inc.

Terminated

A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Lymphoid Malignancies

United States, United Kingdom
Lumara Health, Inc.

Completed

Pain Associated With Endometriosis

Endometriosis

United States, Russian Federation, Canada
Lumara Health, Inc.

Completed

Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood

Pregnancy

United States
Lumara Health, Inc.

Completed

Vaginal Infection Study 2

Vaginal Infection

United States, Russian Federation, India
Lumara Health, Inc.

Completed

Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort

Vulvodynia

United States, Canada
Lumara Health, Inc.

Completed

Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms

Hot Flashes

United States
Lumara Health, Inc.

Completed

Vaginal Infection Study

Vaginitis | Vulvovaginitis

United States, Russian Federation, Puerto Rico, India
Human Genome Sciences Inc.
GlaxoSmithKline

Terminated

Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

United States, Mexico
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

Study of Belimumab Administered Subcutaneously to Healthy Subjects

Healthy

United States
RAND
Bienestar Human Services, Inc.

Recruiting

A Cognitive Behavioral Therapy Group Intervention to Increase HIV Testing and PrEP Use Among Latinx Sexual Minority Men

HIV

United States
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76)

Systemic Lupus Erythematosus

United States, Spain, Israel, Netherlands, Canada, Germany, Poland, Romania, Puerto Rico, Costa Rica, Belgium, Slovakia, United Kingdom, Mexico, Italy, Austria, Czech Republic, Sweden, France
Human Genome Sciences Inc.
GlaxoSmithKline

Completed

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-52)

Systemic Lupus Erythematosus

Hong Kong, Taiwan, Korea, Republic of, India, Chile, Argentina, Philippines, Colombia, Brazil, Romania, Australia, Peru, Russian Federation
Novartis
Human Genome Sciences Inc.

Completed

Safety and Efficacy of Albumin Interferon Administered Every 4 Weeks in Genotype 2/3 Hepatitis C Patients

Chronic Hepatitis C

Taiwan, Germany, Greece, Italy, Spain, United Kingdom, France, Canada, Australia, India, Poland, Thailand
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76

Systemic Lupus Erythematosus
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Chronic Hepatitis C

Korea, Republic of, United States, Spain, Canada, France, Australia, Israel, Singapore, Thailand, Malaysia, Sweden, Belgium, Germany, Taiwan, Poland, Argentina, India, Puerto Rico, Brazil, Mexico, United Kingdom
Human Genome Sciences Inc.
Novartis

Completed

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

Chronic Hepatitis C

United States, Spain, Canada, France, Australia, Italy, Israel, Poland, United Kingdom, Germany, Czech Republic, Romania, Austria, India, Puerto Rico
RAND
Bienestar Human Services, Inc.

Completed

A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM

HIV

United States
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115

Systemic Lupus Erythematosus

Korea, Republic of, Japan
GlaxoSmithKline
Human Genome Sciences Inc.

Completed

GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

Systemic Lupus Erythematosus

Korea, Republic of, China, Japan
Anumana, Inc.
Mayo Clinic

Not yet recruiting

A Multicenter Pragmatic Implementation Study of ECG-AI-Based Clinical Decision Support Software to Identify Low LVEF (AIM ECG-AI)

Ventricular Ejection Fraction

United States
Mayo Clinic
Anumana, Inc.

Completed

A Multi-Center Study of Detection of Low Ventricular Ejection Fraction

Cardiac Disease

United States
Center for Human Reproduction
FertiliTech Inc.

Terminated

Comparison Of The Embryoscope Time-Lapse System With Standard Embryo Culture

Infertility

United States
TruDiagnostic
L-Nutra Inc; Peak Human Labs

Active, not recruiting

The Impact of a Fast Diet and Calorie Mimetic Supplements on Epigenetic Aging

Aging

Canada
Human Genome Sciences Inc.
GlaxoSmithKline; Emergent BioSolutions

Completed

An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection

Therapeutic Treatment of Inhalation Anthrax
Human Genome Sciences Inc.
GlaxoSmithKline; Emergent BioSolutions

Completed

A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects

Healthy
Novartis Pharmaceuticals
Human Genome Sciences Inc.

Terminated

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Chronic Hepatitis B

Taiwan, Poland, China, Hong Kong, Thailand
University of Pennsylvania
Human Genome Sciences Inc.

Terminated

Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant

Desensitization

United States
RAND
Columbia University; Bienestar Human Services, Inc.

Completed

Using Mobile Technology and Incentives With Men Who Have Sex With Men and Transgender Women for HIV Prevention (MOTIVES)

HIV Infections | HIV

United States

Clinical Trials Sponsored by Humana Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations